Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
With
National Institute of Mental Health (NIMH)
PDD can be a profoundly disabling condition across social, emotional, and academic domains. Safe and effective treatments for PDD are needed.
Participants are randomly assigned to receive either risperidone plus parent management training or risperidone alone for 24 weeks. Participants who show deterioration at Week 4 will be offered an alternative mediation treatment, aripiprazole. These participants will remain in their original treatment group (either med alone or med plus parent management training). After 6 months of treatment (Week 24), participants who respond to their treatment will be gradually discontinued from their medication treatment to learn if the response can be sustained without continued medication treatment (This phase of the study was ended in Nov. 2006) Adaptive and behavioral outcomes are assessed during the study.
Age
4–13
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Autistic Disorder, Asperger's Disorder, or Pervasive Developmental Disorder not otherwise specified
Weight \> 30 lbs
IQ \>= 35 or mental age of at least 18 months
You may not be if
Psychotic Disorder
History of intolerance or nonresponse to risperidone